NuVasive (NASDAQ:NUVA) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, October 30th. Analysts expect the company to announce earnings of $0.63 per share for the quarter. NuVasive has set its FY18 guidance at $2.37-2.40 EPS.
NuVasive (NASDAQ:NUVA) last released its earnings results on Tuesday, July 31st. The medical device company reported $0.58 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.58. The business had revenue of $281.56 million for the quarter, compared to analyst estimates of $276.05 million. NuVasive had a net margin of 3.96% and a return on equity of 13.70%. On average, analysts expect NuVasive to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
NUVA stock opened at $63.59 on Tuesday. The firm has a market capitalization of $3.19 billion, a P/E ratio of 33.29, a PEG ratio of 1.70 and a beta of 0.69. NuVasive has a 12-month low of $44.62 and a 12-month high of $72.41.
NUVA has been the topic of several recent analyst reports. Needham & Company LLC dropped their target price on shares of NuVasive from $69.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, August 1st. Robert W. Baird upgraded shares of NuVasive from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $60.00 to $82.00 in a report on Thursday, September 27th. ValuEngine upgraded shares of NuVasive from a “strong sell” rating to a “sell” rating in a report on Monday, July 30th. Zacks Investment Research lowered shares of NuVasive from a “hold” rating to a “sell” rating in a report on Tuesday, July 3rd. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $58.00 price objective on shares of NuVasive in a report on Friday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $68.56.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.